Serum Concentrations of HGF Are Correlated With Response To Anti-PD-1 Antibody Therapy in Patients with Metastatic Melanoma

Journal of Dermatological Science
09 Feb, 2019 ,

In this, they evaluate whether the serum concentration of HGF can be used as a biomarker for the clinical response to anti-PD-1 antibody therapy. This study included 29 metastatic melanoma patients receiving nivolumab or pembrolizumab. Results suggested that c-MET inhibition promotes perforin expression in CD8+ T cells. Therefore, c-MET inhibitors can activate the immune system and may play an important role in combined immunotherapy.